Navigation Links
Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
Date:5/16/2012

BLUE BELL, Pa., May 16, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines. By design, Inovio's SynCon® flu vaccine is not matched to any single virus. Importantly, the vaccine generated a hemagglutination inhibition (HAI) titer of 1:40 or higher against at least one of the six tested H5N1 strains in 8 of 17 (47%) immunized subjects, demonstrating the vaccine's broad coverage; 12 of 17 (71%) vaccines generated an HAI titer of 1:20 or higher, indicating a positive vaccine response, against at least one H5N1 strain.

Dr. J. Joseph Kim, Inovio's president and CEO, said: "Our goal has been to develop a truly universal influenza vaccine capable of providing years of protection across subtypes and strains. The protective levels of antibody responses generated by our universal H5N1 vaccine against diverse unmatched strains of this dangerous subtype provides proof of principle for our SynCon universal flu program and our other antibody-based vaccine products. We are planning further development initiatives for this program and look forward to forthcoming data from INO-3510, our universal vaccine for the influenza H5N1 and H1N1."

The major challenge to developing broadly effective vaccines against influenza is that within subtypes there are hundreds of strains that may vary slightly and which naturally and frequently mutate to create new strains. Today's vaccines only provide protection by matching targeted virus strains, which are those predicted to be of concern in the next flu season; however, they often fail to be protective because the predicted strain(s) changes as the next flu season emerges. Of even greater concern, subtypes can reassort, i.e. strains from different subt
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals to Present at SPI 2012
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
4. Inovio Receives U.S. Patent for SynCon® H1N1 Influenza Universal Vaccine
5. Inovio Pharmaceuticals to Present at Biotech Showcase Investor Conference
6. Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference
7. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
8. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
9. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
10. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
11. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014   Plexus Information ... of Anesthesia Information Management Systems (AIMS), announced a ... , a wholly owned subsidiary of Quality Systems, ... systems and connectivity solutions.  Logo ... This partnership extends the ...
(Date:10/1/2014)... -- ResMed (NYSE: RMD ), a pioneer and innovator ... complete sleep apnea solutions specifically for women, is launching a ... good night,s sleep. The Better Sleep For ... is just part of living a busy life. It will ... of health, essential to not only living an active lifestyle ...
(Date:10/1/2014)... 2014 Trovagene, Inc., (NASDAQ:  TROV) a ... Eli Diamond , MD, Assistant Attending Neurologist ... clinical data from an ongoing study demonstrating the ... the determination of oncogene mutational status in cell-free ... were presented to both treating physicians and patients ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... SAN DIEGO, July 9 Arena Pharmaceuticals, ... results from a multiple-ascending,dose Phase 1b clinical ... safety,pharmacokinetics and pharmacodynamics. APD791 is Arena,s internally,discovered ... of arterial,thrombosis and other related conditions., ...
... July 8 After meeting on July 1st ... new diabetes drugs should,undergo trials to rule out ... US endocrinologists agree with this recommendation, according to,AlphaDetail ... market,research and key opinion leader mapping solutions to ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications. 2
(Date:10/2/2014)... October 02, 2014 Social-Engineer, Inc. the ... announced today it will host a complimentary webinar on ... will reveal the final outcome of the annual Social-Engineer ... 22 in Las Vegas and explore how to maximize ... attacks. To register for the webinar go to: ...
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, ... birth control -- especially long-acting implanted devices -- could slash ... average, new findings suggest. In a study of 1,400 ... cut the girls, rates of unplanned pregnancy and abortion. Over ... girls -- versus a rate of 158 per 1,000 among ...
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Medical discovery first step on path to new painkillers 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
... of a landmark study, researchers at Mayo Clinic,s Florida campus ... need to remove colon polyps that are not cancerous or ... to one-half of the polyps removed during colonoscopies end up ... and this increases time, expense and the potential for complications ...
... amo, a destination spa,at Enchantment Resort, for a ... winter solstice on December 21. Activities include a,series ... Program Director R.J. Joseph and special guest, Elder ... from the Blood Reserve,in Standoff, Alberta, Canada,s largest ...
... announcement of planned bequest comes at stem cell symposium, ... one year,ago, retail pioneer A. Alfred Taubman announced a ... a new research institute aimed at,understanding, treating and preventing ... he did it again --,announcing that he will bequeath ...
... Wanted to Know But Was Afraid to Ask!, ... babies born,in the U.S. each year but there,s not ... is a revealing, entertaining and inspirational DVD that,offers invaluable ... gone through the pregnancy and delivery process. It includes,a ...
... LAKE CITY University of Utah researchers have developed a ... to the wall of the heart,s left atrium in patients ... results of the study are published in the Oct. 7, ... of Cardiology . , Atrial fibrillation (AF) is an ...
... ) (OTCBB:WYND), the ideas-to-revenues social media company, ... ( www.muveinc.com ), to create an interactive ... activity-based corporate wellness program. Wyndstorm,s design project ... the use of wellness programs among employees ...
Cached Medicine News:Health News:Mayo Clinic estimates new, tiny, super-sensitive probe could cut colon polyp removal in half 2Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: